Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives

Carbonic anhydrases (CAs) are a group of ubiquitously expressed metalloenzymes that catalyze the reversible hydration/dehydration of CO<sub>2</sub>/HCO<sub>3</sub>. Thus, they are involved in those physiological and pathological processes in which cellular pH buffering plays...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lidia Ciccone, Chiara Cerri, Susanna Nencetti, Elisabetta Orlandini
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/34268ec257b846e1949ff7fc5b004fad
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:34268ec257b846e1949ff7fc5b004fad
record_format dspace
spelling oai:doaj.org-article:34268ec257b846e1949ff7fc5b004fad2021-11-11T18:24:29ZCarbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives10.3390/molecules262163801420-3049https://doaj.org/article/34268ec257b846e1949ff7fc5b004fad2021-10-01T00:00:00Zhttps://www.mdpi.com/1420-3049/26/21/6380https://doaj.org/toc/1420-3049Carbonic anhydrases (CAs) are a group of ubiquitously expressed metalloenzymes that catalyze the reversible hydration/dehydration of CO<sub>2</sub>/HCO<sub>3</sub>. Thus, they are involved in those physiological and pathological processes in which cellular pH buffering plays a relevant role. The inhibition of CAs has pharmacologic applications for several diseases. In addition to the well-known employment of CA inhibitors (CAIs) as diuretics and antiglaucoma drugs, it has recently been demonstrated that CAIs could be considered as valid therapeutic agents against obesity, cancer, kidney dysfunction, migraine, Alzheimer’s disease and epilepsy. Epilepsy is a chronic brain disorder that dramatically affects people of all ages. It is characterized by spontaneous recurrent seizures that are related to a rapid change in ionic composition, including an increase in intracellular potassium concentration and pH shifts. It has been reported that CAs II, VII and XIV are implicated in epilepsy. In this context, selective CAIs towards the mentioned isoforms (CAs II, VII and XIV) have been proposed and actually exploited as anticonvulsants agents in the treatment of epilepsy. Here, we describe the research achievements published on CAIs, focusing on those clinically used as anticonvulsants. In particular, we examine the new CAIs currently under development that might represent novel therapeutic options for the treatment of epilepsy.Lidia CicconeChiara CerriSusanna NencettiElisabetta OrlandiniMDPI AGarticlecarbonic anhydrases (CAs)CA inhibitors (CAIs)epilepsyCA IICA VIICA XIVOrganic chemistryQD241-441ENMolecules, Vol 26, Iss 6380, p 6380 (2021)
institution DOAJ
collection DOAJ
language EN
topic carbonic anhydrases (CAs)
CA inhibitors (CAIs)
epilepsy
CA II
CA VII
CA XIV
Organic chemistry
QD241-441
spellingShingle carbonic anhydrases (CAs)
CA inhibitors (CAIs)
epilepsy
CA II
CA VII
CA XIV
Organic chemistry
QD241-441
Lidia Ciccone
Chiara Cerri
Susanna Nencetti
Elisabetta Orlandini
Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives
description Carbonic anhydrases (CAs) are a group of ubiquitously expressed metalloenzymes that catalyze the reversible hydration/dehydration of CO<sub>2</sub>/HCO<sub>3</sub>. Thus, they are involved in those physiological and pathological processes in which cellular pH buffering plays a relevant role. The inhibition of CAs has pharmacologic applications for several diseases. In addition to the well-known employment of CA inhibitors (CAIs) as diuretics and antiglaucoma drugs, it has recently been demonstrated that CAIs could be considered as valid therapeutic agents against obesity, cancer, kidney dysfunction, migraine, Alzheimer’s disease and epilepsy. Epilepsy is a chronic brain disorder that dramatically affects people of all ages. It is characterized by spontaneous recurrent seizures that are related to a rapid change in ionic composition, including an increase in intracellular potassium concentration and pH shifts. It has been reported that CAs II, VII and XIV are implicated in epilepsy. In this context, selective CAIs towards the mentioned isoforms (CAs II, VII and XIV) have been proposed and actually exploited as anticonvulsants agents in the treatment of epilepsy. Here, we describe the research achievements published on CAIs, focusing on those clinically used as anticonvulsants. In particular, we examine the new CAIs currently under development that might represent novel therapeutic options for the treatment of epilepsy.
format article
author Lidia Ciccone
Chiara Cerri
Susanna Nencetti
Elisabetta Orlandini
author_facet Lidia Ciccone
Chiara Cerri
Susanna Nencetti
Elisabetta Orlandini
author_sort Lidia Ciccone
title Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives
title_short Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives
title_full Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives
title_fullStr Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives
title_full_unstemmed Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives
title_sort carbonic anhydrase inhibitors and epilepsy: state of the art and future perspectives
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/34268ec257b846e1949ff7fc5b004fad
work_keys_str_mv AT lidiaciccone carbonicanhydraseinhibitorsandepilepsystateoftheartandfutureperspectives
AT chiaracerri carbonicanhydraseinhibitorsandepilepsystateoftheartandfutureperspectives
AT susannanencetti carbonicanhydraseinhibitorsandepilepsystateoftheartandfutureperspectives
AT elisabettaorlandini carbonicanhydraseinhibitorsandepilepsystateoftheartandfutureperspectives
_version_ 1718431815569506304